Researchers: Dexamethasone Could Improve Survival Rate in New Coronary Pneumonia Patients

The u.S. Food and Drug Administration (FDA) has just revoked the emergency use of hydroxychloroquine, which Mr. Trump pushed to “test in person,” and British researchers say they have found a drug that could improve the survival of patients with new coronary pneumonia. British researchers have discovered the drug, an asynthetic steroid, dexamethasone, the Associated Press reported Thursday.

The drug, which can be taken orally or intravenously, can reduce mortality by 35 percent for patients with severe pneumonia who need a ventilator, and 20 percent for patients who need oxygen supplements, but it does not seem to have a role in patients with mild conditions.

Researchers: Dexamethasone Could Improve Survival Rate in New Coronary Pneumonia Patients

Dexamethason

British researchers said they conducted a large, rigorous test of the treatment of neo-coronary pneumonia, randomly assigning 2,104 patients to take dexamethasone and comparing them with 4,321 patients who received only routine treatment. The results of the test were announced on the 16th, the relevant research content is said to be published soon.

“This is a welcome result,” Peter Horby, professor of infectious diseases and public health at Oxford University and the study’s leader, said in a statement. For patients with severe conditions that require oxygen, the survival rate is significant, so dexamethasone should be the standard treatment for these patients. And the dexamethasone is cheap and shelves are everywhere and can be used immediately to save lives around the world. “

Researchers in the UK, funded by the UK government and private donors, recruited 11,000 patients with new coronary pneumonia from England, Scotland, Wales and Northern Ireland to test treatment for the disease, the Associated Press reported. These people are either subjected to the current standard treatment for new coronary pneumonia or treatment, including the anti-AIDS drug lopinavir/litonevir, azithromycin, dexamethasone, the anti-inflammatory drug tozhuzumab and the plasma of the recovered person. At present, other treatment research is continuing.

Notably, the study also found that the antimalarial drug hydroxychloroquine, which Mr. Trump had previously recommended and personally, did not work with the new coronavirus.

The U.S. Food and Drug Administration announced on the 15th that it was withdrawing emergency use of chloroquine and hydroxychloroquine, saying the drugs were “unlikely to be effective in treating new coronavirus pneumonia,” CNBC reported earlier. “

Denise Hinton, the agency’s chief scientist, added in a statement: “Given the severe heart events and other serious side effects caused by such drugs, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh their known and potential risks … As a result, this Council has revoked the emergency use of these two drugs for the treatment of new coronary pneumonia. “

On the other hand, the Gilead Science website released a statement earlier this month on the drug’s overall clinical data about the high-profile Redsiwe, which is highly regarded. The statement said overall clinical data showed that Redsewey could provide significant benefits to patients with new coronary pneumonia and offer great promise.

At present, Redsiwe is approved in Japan for the treatment of patients infected with the new coronavirus, according to Gilead. Outside Japan, Redseweist is an unapproved drug. The U.S. Food and Drug Administration granted Redsewe emergency use authorization to treat hospitalized patients with severe pneumonia in the new crown. Clinical data on Redseweare are limited. Use of Redsevemay may have previously unreported serious and unexpected adverse events.

At the end of April, the Lancet website, an internationally renowned medical journal, published the results of a Redsiwe trial conducted by a Chinese team. The results showed that there was no statistically significant clinical benefit to Redsewe combined standard therapy compared to standard therapy.

Professor Cao Bin, of sino-Japanese Friendship Hospital and Capital Medical University, who led the study, said: “This trial found no significant benefits compared to placebos, despite Redsewe’s safety and well-tolerant nature. “